Cath Lab DigestNew Data Confirm Rapid, Unpredictable Progression of Severe Aortic Stenosis and Need for Urgent Referral and Evaluation of Patients

New research presented at the American College of Cardiology’s Annual Scientific Session highlights the rapid, unpredictable progression of severe aortic stenosis (AS) and the critical importance of timely intervention. The DETECT AS randomized controlled trial and new analyses from the EARLY TAVR trial provide level 1 evidence supporting urgent referral and evaluation for all severe AS patients.

⚕️Key Clinical Considerations⚕️

• Without treatment, 1 in 10 patients with symptomatic severe AS may die within five weeks, underscoring the urgency of proper diagnosis and referral.
• The DETECT AS study (n=939) demonstrated that electronic echo alerts increased aortic valve replacement rates by 11% overall and 14% in symptomatic patients, with greater improvements among older patients and women.
• EARLY TAVR trial data confirmed superior outcomes with timely TAVR intervention compared to guideline-recommended clinical surveillance (“watchful waiting”) in asymptomatic severe AS patients.
• New analysis of EARLY TAVR data revealed that severity of symptoms at conversion to AVR impacts outcomes, reinforcing that delayed intervention is not an effective management strategy.
• Cardiac biomarkers were not predictive of optimal timing for intervention, highlighting the unpredictable disease progression and need for prompt evaluation upon diagnosis.

🎯 Clinical Practice Impact 🎯

• Patient Communication: Educate patients about the potentially rapid progression of severe AS and the limitations of symptom monitoring, emphasizing that symptoms may be subtle or easily attributed to aging.
• Practice Integration: Implement systematic electronic echo alerts when severe AS is detected to improve treatment rates and reduce age and gender disparities in care.
• Risk Management: Reconsider “watchful waiting” strategies given evidence that asymptomatic severe AS patients benefit from timely intervention without clinical penalty.
• Action Items: Establish clear referral pathways to structural heart teams for all severe AS patients, regardless of symptom status, with urgency following diagnosis.
• Assessment Tools: Recognize limitations of cardiac biomarkers for predicting disease progression and rely on comprehensive clinical evaluation rather than isolated markers.

More on Aortic Stenosis